tenk.fyi

NEOGEN CORP

NEOGNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$894.7M

3.2% YoY

Net Income

-$1.1B

11491.6% YoY

EPS

$-5.03

12475.0% YoY

Cash

$129.0M

24.4% YoY

FY 2025 · As of 2025-05-31